Nature Study Finds In Vivo and In Vitro Commensal Metabolomes Produce Distinct GPCR Activation Profiles

A study published in Nature on 8 June 2026 examined GPCR activation by metabolites from 100 commensal bacterial strains grown either in monoassociated germ-free mice or in bacterial culture medium. The multiplexed screening revealed that in vivo and in vitro metabolomes produced different receptor activation profiles.

Three mechanisms accounted for the differences: host-mediated metabolite degradation, in vivo microbial metabolic reprogramming, and bacterial conversion of dietary substrates.

The paper, titled 'Commensal-derived acetylcholine enhances mucosal immune education,' lists microbiome and mucosal immunology as its subjects. Multiple strains converted dietary choline into acetylcholine in the mouse gut. Select Bifidobacterium strains that dominate the early-life microbiome and one probiotic Pediococcus strain performed the conversion.

Researchers identified the bacterial enzymes responsible in Bifidobacterium breve and Pediococcus pentosaceus. An isogenic mutant of B. breve unable to produce acetylcholine was generated for comparison.

Mice colonized with the acetylcholine-producing strain showed higher intestinal immunoglobulin A levels, shifts in microbiota composition, and greater resistance to enteric infection. The abstract states that these results demonstrate a diet–microbiome–host axis that strengthens mucosal immune defences.

The microbiota is described as producing thousands of potentially bioactive small molecules, and prior high-throughput screens had already linked some metabolites to GPCR signaling.

A related open-access paper on gut microbiome composition in wild redfronted lemurs appeared in December 2022.